Loading...
The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'.
Schöffski, P Wozniak, A Leahy, Michael G Aamdal, S Rutkowski, P Bauer, S Richter, S Grünwald, V Debiec-Rychter, M Sciot, R
Schöffski, P
Wozniak, A
Leahy, Michael G
Aamdal, S
Rutkowski, P
Bauer, S
Richter, S
Grünwald, V
Debiec-Rychter, M
Sciot, R
Citations
Altmetric:
Abstract
Alveolar rhabdomyosarcomas (ARMSs) can harbour MET and anaplastic lymphoma kinase (ALK) alterations. We prospectively assessed crizotinib in patients with advanced/metastatic ARMS.
Description
Date
2018-05
Publisher
Collections
Keywords
Type
Article
Citation
The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'. 2018, 94: 156-167 Eur J Cancer